About this trial
Context Acute liver failure (ALF) is a life-threatening condition that occurs on the background of a healthy liver. The most common cause of acute liver failure in the UK is paracetamol overdose. Acute liver failure results from liver damage and activation of the body's inflammatory defences with subsequent damage to other organs including kidneys, lungs and heart. This often requires life support in an intensive care unit before liver transplantation (LT), the only currently available and effective rescue treatment for acute liver failure.
Challenge Patient factors and organ availability limit who can benefit from liver transplant. At present there are no effective alternative therapies for patients who do not get a liver transplant, and survival rates in these situations are poor. The underlying mechanisms of inflammation are poorly understood, thus therapies are limited.
Aim The investigators research aims to understand the mechanisms that underpin the inflammation seen in acute liver failure by studying the inflammatory cells in the blood and examining their cellular programmes. This will allow the investigators to identify pathways that are activated and understand how the liver and blood interact to spread inflammation around the body. The investigators aim to identify targets for disease-modifying therapies to avert the need for liver transplant.
Importance Understanding how the body responds to acute liver failure, and whether there are different patterns of inflammatory response, will enable trials of immune-modulating drugs to prevent the need for liver transplantation or prolong the time a patient can wait for an organ. This has the potential to help improve organ availability for other patients and save lives in acute liver failure.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
acute liver failure due to acetaminophen (paracetamol) overdose admitted to ICU
all cause sepsis admitted to ICU
Disqualifiers
age <16y
Trial population
Patients with acute liver failure due to acetaminophen overdose OR sepsis who are admitted to ICU
Trial design
Cohort
Prospective
Treatments tested in this trial
blood draw
Other interventionVenous blood sampling into Tempus tube for RNA-sequencing
Treatment groups
Trial outcomes
Primary outcomes
Mortality
Secondary outcomes
Transplant free survival
30-day and 1-year survival without transplant
Length of stay - ICU and hospital
Number of days stayed in ICU and in-hospital
Transplant free mortality
Death without transplant
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
University of Cambridge
Lead sponsor
European Society of Intensive Care Medicine
Collaborator
This trial is not recruiting at the moment. You can still explore other options: